Liu Jean I returned $11,163,292 worth of shares to the company (48,748 units at $229.00), closing all direct ownership in the company (SEC Form 4)

$SGEN
Biotechnology: Biological Products (No Diagnostic Substances)
Health Care
Get the next $SGEN alert in real time by email
SEC FORM 4 SEC Form 4
FORM 4 UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940
OMB APPROVAL
OMB Number: 3235-0287
Estimated average burden
hours per response: 0.5
X
Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).
  
Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.
1. Name and Address of Reporting Person*
LIU JEAN I

(Last) (First) (Middle)
21823 30TH DR. SE

(Street)
BOTHELL WA 98021

(City) (State) (Zip)
2. Issuer Name and Ticker or Trading Symbol
Seagen Inc. [ SGEN ]
5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)
Director 10% Owner
X Officer (give title below) Other (specify below)
Chief Legal Officer
3. Date of Earliest Transaction (Month/Day/Year)
12/14/2023
4. If Amendment, Date of Original Filed (Month/Day/Year)
6. Individual or Joint/Group Filing (Check Applicable Line)
X Form filed by One Reporting Person
Form filed by More than One Reporting Person
Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3) 2. Transaction Date (Month/Day/Year) 2A. Deemed Execution Date, if any (Month/Day/Year) 3. Transaction Code (Instr. 8) 4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5) 5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4) 6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 7. Nature of Indirect Beneficial Ownership (Instr. 4)
Code V Amount (A) or (D) Price
Common Stock 12/14/2023 D(1) 48,748 D $229(1)(2) 0 D
Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned
(e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3) 2. Conversion or Exercise Price of Derivative Security 3. Transaction Date (Month/Day/Year) 3A. Deemed Execution Date, if any (Month/Day/Year) 4. Transaction Code (Instr. 8) 5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5) 6. Date Exercisable and Expiration Date (Month/Day/Year) 7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4) 8. Price of Derivative Security (Instr. 5) 9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4) 10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 11. Nature of Indirect Beneficial Ownership (Instr. 4)
Code V (A) (D) Date Exercisable Expiration Date Title Amount or Number of Shares
Stock Options (Right to Buy) $39.15 12/14/2023 D(1) 7,446 (3) 08/25/2025 Common stock 7,446 (3) 0 D
Stock Options (Right to Buy) $45.3 12/14/2023 D(1) 35,293 (3) 08/27/2026 Common stock 35,293 (3) 0 D
Stock Options (Right to Buy) $46.37 12/14/2023 D(1) 40,344 (3) 08/17/2027 Common stock 40,344 (3) 0 D
Stock Options (Right to Buy) $76.86 12/14/2023 D(1) 40,523 (3) 08/30/2028 Common stock 40,523 (3) 0 D
Stock Options (Right to Buy) $72.64 12/14/2023 D(1) 1,333 (3) 08/30/2029 Common stock 1,333 (3) 0 D
Stock Options (Right to Buy) $72.64 12/14/2023 D(1) 43,786 (3) 08/30/2029 Common stock 43,786 (3) 0 D
Stock Options (Right to Buy) $161.82 12/14/2023 D(1) 636 (3) 08/17/2030 Common stock 636 (3) 0 D
Stock Options (Right to Buy) $161.82 12/14/2023 D(1) 17,205 (3) 08/17/2030 Common stock 17,205 (3) 0 D
Stock Options (Right to Buy) $155.87 12/14/2023 D(1) 642 (3) 08/16/2031 Common stock 642 (3) 0 D
Stock Options (Right to Buy) $155.87 12/14/2023 D(1) 21,915 (3) 08/16/2031 Common stock 21,915 (3) 0 D
Restricted Stock Units (4) 12/14/2023 D(1) 1,798 (4) (4) Common stock 1,798 (4) 0 D
Restricted Stock Units (4) 12/14/2023 D(1) 4,622 (4) (4) Common stock 4,622 (4) 0 D
Restricted Stock Units (4) 12/14/2023 D(1) 4,436 (4) (4) Common stock 4,436 (4) 0 D
Restricted Stock Units (4) 12/14/2023 D(1) 10,298 (4) (4) Common stock 10,298 (4) 0 D
Restricted Stock Units (5) 12/14/2023 D(1) 1,389 (5) (5) Common stock 1,389 (5) 0 D
Restricted Stock Units (5) 12/14/2023 D(1) 13,107 (5) (5) Common stock 13,107 (5) 0 D
Performance Stock Units (6) 12/14/2023 D(1) 2,708 (6) (6) Common stock 2,708 (6) 0 D
Performance Stock Units (6) 12/14/2023 D(1) 3,662 (6) (6) Common stock 3,662 (6) 0 D
Performance Stock Units (6) 12/14/2023 D(1) 583 (6) (6) Common stock 583 (6) 0 D
Performance Stock Units (6) 12/14/2023 D(1) 5,554 (6) (6) Common stock 5,554 (6) 0 D
Performance Stock Units (6) 12/14/2023 D(1) 9,423 (6) (6) Common stock 9,423 (6) 0 D
Performance Stock Units (6) 12/14/2023 D(1) 12,688 (6) (6) Common stock 12,688 (6) 0 D
Performance Stock Units (6) 12/14/2023 D(1) 1,457 (6) (6) Common stock 1,457 (6) 0 D
Performance Stock Units (6) 12/14/2023 D(1) 874 (6) (6) Common stock 874 (6) 0 D
Performance Stock Units (7) 12/14/2023 D(1) 1,305 (7) (7) Common stock 1,305 (7) 0 D
Performance Stock Units (8) 12/14/2023 D(1) 1,165 (8) (8) Common stock 1,165 (8) 0 D
Performance Stock Units (8) 12/14/2023 D(1) 2,912 (8) (8) Common stock 2,912 (8) 0 D
Performance Stock Units (8) 12/14/2023 D(1) 1,747 (8) (8) Common stock 1,747 (8) 0 D
Explanation of Responses:
1. Reflects the disposition of shares of common stock, par value $0.001 per share ("Common Stock"), of Seagen Inc. ("Issuer"), or of equity awards in respect of such Common Stock, as applicable, in connection with the consummation of the transactions contemplated by the Agreement and Plan of Merger, dated as of March 12, 2023 (the "Merger Agreement"), by and among the Issuer, Pfizer Inc. ("Parent") and Aris Merger Sub, Inc. ("Merger Sub"), a wholly owned subsidiary of Parent, pursuant to which, at 12:01 a.m. EST on December 14, 2023, the effective time of the Merger (the "Effective Time"), Merger Sub merged with and into the Issuer, with the Issuer surviving as a subsidiary of Parent (the "Merger").
2. Pursuant to the Merger Agreement, at the Effective Time, each issued and outstanding share of Common Stock (other than certain excluded shares described in the Merger Agreement) was cancelled and converted automatically into the right to receive cash in an amount equal to $229.00 per share of Common Stock (the "Merger Consideration").
3. Pursuant to the Merger Agreement, each outstanding option, whether or not then vested, was cancelled in exchange for the right to receive an amount in cash equal to the product of (i) the excess, if any, of the Merger Consideration over the per-share exercise price of such option, multiplied by (ii) the number of shares of Common Stock then subject to such option.
4. Pursuant to the Merger Agreement, at the Effective Time, each outstanding restricted stock unit (each, a "Company RSU"), other than any Post-Signing Company RSU (as defined below), was cancelled and converted into the right to receive an amount in cash equal to the product of (i) the Merger Consideration, multiplied by (ii) the number of shares of Common Stock then subject to such Company RSU.
5. Pursuant to the Merger Agreement, at the Effective Time, each outstanding Company RSU granted after March 12, 2023 that was unvested as of immediately prior to the Effective Time (each, a "Post-Signing Company RSU") was cancelled and converted into the right to receive a Parent cash-based award subject to service-based vesting requirements with respect to an amount in cash equal to the product of (i) the Merger Consideration, multiplied by (ii) the number of shares of Common Stock then subject to such Post-Signing Company RSU.
6. Pursuant to the Merger Agreement, at the Effective Time, each outstanding performance-based restricted stock unit (each, a "Company PSU"), other than any Company Products PSU or any Company August 2023 PSU (each, as defined below), was cancelled and converted into the right to receive cash equal to the product of (i) the Merger Consideration, multiplied by (ii) the number of shares of Common Stock then subject to such Company PSU, based on the greater of the target and actual performance. Amounts are shown here based on actual performance.
7. Pursuant to the Merger Agreement, at the Effective Time, each outstanding "Company Products PSU" (as defined in the Merger Agreement) that was unvested as of immediately prior to the Effective Time was cancelled and converted into the right to receive a Parent cash-based award subject to the same performance-based vesting requirements with respect to an amount in cash that is equal to the product of (i) the Merger Consideration, multiplied by (ii) the number of shares of Common Stock then subject to such Company Products PSU.
8. Pursuant to the Merger Agreement, at the Effective Time, each outstanding performance-based restricted stock unit granted in August 2023 (each, a "Company August 2023 PSU") that was unvested as of immediately prior to the Effective Time, was cancelled and converted into the right to receive a Parent cash-based award with respect to an amount in cash equal to the product of (i) the Merger Consideration, multiplied by (ii) the number of shares of Common Stock then subject to such Company August 2023 PSU, based on target performance.
/s/ Jennifer Prosba, Attorney-in-Fact 12/15/2023
** Signature of Reporting Person Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
Get the next $SGEN alert in real time by email

Chat with this insight

Save time and jump to the most important pieces.

Recent Analyst Ratings for
$SGEN

DatePrice TargetRatingAnalyst
2/16/2023$140.00 → $175.00In-line → Outperform
Evercore ISI
2/16/2023$155.00 → $175.00Outperform → Strong Buy
Raymond James
2/6/2023$162.00 → $141.00Outperform → Market Perform
SVB Securities
11/21/2022$135.00Hold
Truist
10/11/2022$177.00 → $178.00Market Perform → Outperform
BMO Capital Markets
6/29/2022$220.00Outperform
Raymond James
6/24/2022$169.00Market Perform
BMO Capital Markets
2/16/2022$201.00 → $142.00Market Outperform
JMP Securities
More analyst ratings

$SGEN
Press Releases

Fastest customizable press release news feed in the world

See more
  • Alltrna Announces Updates to Its Board of Directors

    Chris Schade appointed as Board ChairpersonLynne Parshall, Robert Plenge, M.D., Ph.D., and Nancy Simonian, M.D., appointed to Board of DirectorsCAMBRIDGE, Mass., July 17, 2024 /PRNewswire/ -- Alltrna, a Flagship Pioneering company unlocking transfer RNA (tRNA) biology and pioneering tRNA therapeutics to regulate the protein universe and resolve disease, today announced the appointment of Chris Schade, Growth Partner at Flagship Pioneering, as Chairperson of the Board, succeeding Noubar Afeyan, Ph.D., Co-Founder of Alltrna and Founder and CEO of Flagship Pioneering. In addition, Alltrna also announced the appointments to the company's Board of Directors of Lynne Parshall, founding Chief Opera

    $APRE
    $CYTK
    $EVLO
    $FHTX
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Medical/Dental Instruments
    Biotechnology: Biological Products (No Diagnostic Substances)
  • Pfizer Completes Acquisition of Seagen

    Further establishes Pfizer as a leading oncology company poised to accelerate the next generation of breakthrough treatments for people with cancer To address U.S. Federal Trade Commission concerns, Pfizer has chosen to irrevocably donate the rights of royalties from sales of Bavencio® (avelumab) in the U.S. to the American Association for Cancer Research (AACR) Pfizer Inc. (NYSE:PFE) today announced the successful completion of its acquisition of Seagen Inc. (NASDAQ:SGEN), a global biotechnology company that discovers, develops and commercializes transformative cancer medicines. Pfizer completed its acquisition of all outstanding common stock of Seagen for $229 in cash per share, fo

    $PFE
    $SGEN
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Biotechnology: Biological Products (No Diagnostic Substances)
  • Update: Annual Changes to the Nasdaq-100® Index

    NEW YORK, Dec. 12, 2023 (GLOBE NEWSWIRE) -- Nasdaq (NASDAQ:NDAQ) today announced an update to the annual reconstitution of the Nasdaq-100 Index® (NASDAQ:NDX). Per the announcement by Pfizer Inc. (NYSE:PFE), the pending acquisition of Seagen, Inc. (NASDAQ:SGEN) is expected to close on December 14, 2023. As a result, Take-Two Interactive Software, Inc. (NASDAQ:TTWO), will be added to the Nasdaq-100 Index® and Seagen, Inc. will be removed as part of the annual reconstitution, which will become effective prior to market open on Monday, December 18, 2023. The other constituent changes from the initial announcement by Nasdaq on Friday, December 8, 2023, will remain the same. Information For i

    $NDAQ
    $PFE
    $SGEN
    $TTWO
    Investment Bankers/Brokers/Service
    Finance
    Biotechnology: Pharmaceutical Preparations
    Health Care

$SGEN
Analyst Ratings

Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

See more

$SGEN
Insider Trading

Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

See more

$SGEN
SEC Filings

See more

$SGEN
Leadership Updates

Live Leadership Updates

See more
  • Alltrna Announces Updates to Its Board of Directors

    Chris Schade appointed as Board ChairpersonLynne Parshall, Robert Plenge, M.D., Ph.D., and Nancy Simonian, M.D., appointed to Board of DirectorsCAMBRIDGE, Mass., July 17, 2024 /PRNewswire/ -- Alltrna, a Flagship Pioneering company unlocking transfer RNA (tRNA) biology and pioneering tRNA therapeutics to regulate the protein universe and resolve disease, today announced the appointment of Chris Schade, Growth Partner at Flagship Pioneering, as Chairperson of the Board, succeeding Noubar Afeyan, Ph.D., Co-Founder of Alltrna and Founder and CEO of Flagship Pioneering. In addition, Alltrna also announced the appointments to the company's Board of Directors of Lynne Parshall, founding Chief Opera

    $APRE
    $CYTK
    $EVLO
    $FHTX
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Medical/Dental Instruments
    Biotechnology: Biological Products (No Diagnostic Substances)
  • Seagen Appoints Sandra M. Swain, M.D., to Board of Directors

    Seagen Inc. (NASDAQ:SGEN) today announced that Sandra M. Swain, M.D., has been appointed to the company's Board of Directors. Dr. Swain has more than 30 years of breast cancer clinical research experience. She currently serves as Associate Dean for Research Development and Professor of Medicine at Georgetown University Medical Center and is the Vice President of Genetic Medicine for MedStar Health. She is also on the Conquer Cancer Foundation Board of American Society of Clinical Oncology (ASCO) and chairs the Women Who Conquer Cancer committee. "We are pleased to welcome Sandra to our Board of Directors given her extensive research and clinical trial experience, especially in HER2-positiv

    $SGEN
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care
  • Seagen Announces Resignation of President, Chairman & CEO Clay Siegall

    Felix Baker, Ph.D., Appointed Chair of the Board Board Begins Search for New CEO Roger Dansey, M.D., Chief Medical Officer, Remains Interim CEO Seagen Inc. (NASDAQ:SGEN) today announced that the Board of Directors yesterday accepted the resignation of Clay Siegall, Ph.D., as President, CEO and member of the Board of Directors. Felix J. Baker, Ph.D., formerly Lead Independent Director, has been appointed Chair of the Board of Directors. Roger Dansey, M.D., Seagen's Chief Medical Officer since 2018, will continue as interim CEO until a new CEO is found. The Board had previously announced that Dr. Siegall was on a leave of absence and that it had formed a committee of independent directors

    $SGEN
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

$SGEN
Financials

Live finance-specific insights

See more
  • Update: Annual Changes to the Nasdaq-100® Index

    NEW YORK, Dec. 12, 2023 (GLOBE NEWSWIRE) -- Nasdaq (NASDAQ:NDAQ) today announced an update to the annual reconstitution of the Nasdaq-100 Index® (NASDAQ:NDX). Per the announcement by Pfizer Inc. (NYSE:PFE), the pending acquisition of Seagen, Inc. (NASDAQ:SGEN) is expected to close on December 14, 2023. As a result, Take-Two Interactive Software, Inc. (NASDAQ:TTWO), will be added to the Nasdaq-100 Index® and Seagen, Inc. will be removed as part of the annual reconstitution, which will become effective prior to market open on Monday, December 18, 2023. The other constituent changes from the initial announcement by Nasdaq on Friday, December 8, 2023, will remain the same. Information For i

    $NDAQ
    $PFE
    $SGEN
    $TTWO
    Investment Bankers/Brokers/Service
    Finance
    Biotechnology: Pharmaceutical Preparations
    Health Care
  • Pfizer Receives All Required Regulatory Approvals to Complete the Acquisition of Seagen

    Expects to close Seagen acquisition on December 14, 2023 Announces changes in the commercial organization to incorporate Seagen and improve focus, speed and execution Pfizer to host analyst and investor call at 8:30 am EST on Wednesday, December 13, 2023, to discuss the Seagen acquisition, new commercial organization, and provide full-year 2024 financial guidance Pfizer Inc. (NYSE:PFE) today announces that the waiting period under the Hart-Scott-Rodino Antitrust Improvements Act of 1976, as amended, expired December 11, 2023, with respect to Pfizer's pending acquisition of Seagen Inc. (NASDAQ:SGEN). Pfizer and Seagen have now received all required regulatory approvals to complete

    $PFE
    $SGEN
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Biotechnology: Biological Products (No Diagnostic Substances)
  • Seagen Third Quarter 2023 Financial Results Reflect Strong Product Sales Growth, and Significant Portfolio and Pipeline Progress

    -Record Net Product Sales of $571 Million in 3Q23, a 33% Increase Over 3Q22, Primarily Driven by PADCEV® First-Line Launch- -PADCEV with Keytruda® Potentially Practice Changing for First-Line Metastatic Urothelial Cancer after EV-302 Trial Demonstrates Near Doubling of Median Overall Survival- -Proposed Pfizer Transaction On-Track and Anticipated to Close in Late-2023 or Early-2024, Subject to Closing Conditions, with Ongoing FTC Review and Recent EC Approval- Seagen Inc. (NASDAQ:SGEN) (Seagen or the Company) reported financial results today for the third quarter ended September 30, 2023. David Epstein, Chief Executive Officer of Seagen said, "Seagen continues to build momentum in 2

    $SGEN
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

$SGEN
Large Ownership Changes

This live feed shows all institutional transactions in real time.

See more